Keenholtz Steven L MD is categorized under Infectious Disease Specialists in Danvers, MA and active since 1986.
Keenholtz Steven L MD was established in 1986, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Infectious Disease Specialists business, which does work in the B2C market, and is classified as a Infectious Disease Specialists, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Steven Keenholtz at the company’s single location by writing to 140 Commonwealth Avenue # 208, Danvers, Massachusetts MA 01923 or by phoning (978) 777-4113. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Keenholtz Steven L MD |
Contact Person: | Steven Keenholtz |
Address: | 140 Commonwealth Avenue # 208, Danvers, Massachusetts 01923 |
Phone Number: | (978) 777-4113 |
Annual Revenue (USD): | $500.000 to $999.999 |
Founded: | 1986 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Infectious Disease Specialists |
SIC Code: | 8011 |
NAICS Code: | 6211110 |
Share This Business: |
Keenholtz Steven L MD was started in 1986 to provide professional Infectious Disease Specialists under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Steven Keenholtz for inquiries that concern Keenholtz Steven L MD by calling the company number (978) 777-4113, as your correspondence is most welcome. Additionally, the physical location of the single location of Keenholtz Steven L MD can be found at the coordinates 42.552972,-70.941824 as well as the street address 140 Commonwealth Avenue # 208 in Danvers, Massachusetts 01923.
For its online presence, you may visit Keenholtz Steven L MD’s website at and engage with its social media outlets through on Twitter and on Facebook.